Robert More

AMO Development LLC designs, develops and manufactures femtosecond laser technology for use in ophthalmology. It offers Keratoplasty a blade-free laser approach used to incise corneal tissue. The firm's products include metal cone and glass lens for disposable patient interface. The company was founded in 1997 and is headquartered in Irvine, CA.

PatientKeeper, Inc. provides healthcare applications for physicians. Its clinical solutions include Computerized Physician Order Entry (CPOE), Mobile CPOE, Medication Reconciliation, NoteWriter, Mobile Clinical Results, Physician Portal, ePrescription, Sign-Out, eSignature and Provider Directory. The firm’s financial solutions include PatientKeeper Charge Capture, PatientKeeper Analytics and PatientKeeper PQRS. It operates through its offices located in Boston and Chicago. The company was founded by Stephen Hau and Joseph Vincent Bonventre in 1996 and is headquartered in Boston, MA.

Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA.

NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Acureon Pharmaceuticals, Inc. develops and markets therapeutics for infectious diseases. The firm’s synergistic combination of anti-infective expertise, dedicated clinical operations, marketing know-how and intellectual property, all coupled with well documented low attrition rates for anti-infective should translate into multiple product opportunities with a lower risk of failure, more rapid development timelines and early substantial returns on investment. The company was founded by Giorgio Mosconi in 2006 and is headquartered in Berwyn, PA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Apnex Medical, Inc. manufactured medical devices. It developed a proprietary active implantable medical device for the treatment of obstructive sleep apnea (OSA). The company was founded by Chad J. Kugler, Michael L. Berman and Robert E. Atkinson in 2006 and was headquartered in St. Paul, MN.

Sirenas LLC research and develops marine inspired pre-clinical leads for cancer, human immunodeficiency virus and infectious diseases. The company was founded by Jake Beverage, Eduardo Esquenazi and Phil Baran and is headquartered in San Diego, CA.

Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.

Morphochem, Inc. manufactures and develops drugs. It uses proprietary whole-cell high throughput screening systems to discover novel compounds of therapeutic value for disorders including cancer & immunological, infectious & metabolic diseases, and for applications in agriculture. The company was founded by Prabhavathi Fernandes in 1997 and is located in Monmouth Junction, NJ

Cytyc Surgical Products II, Inc. was a manufacturer of medical devices. It was established in 1995 to develop site-specific cancer treatment systems for malignant tumors. Some of its products inluded MammoSite RTS for breast cancer and GliaSite RTS for brain cancer. The firm was headquartered in Alpharetta, GA.

Carticept Medical, Inc. develops and markets medical devices. It develops platform technologies to improve the safety, efficiency, and accuracy of many common injection procedures. The firm's Navigator Delivery System, a FDA-cleared computer controlled medication delivery system for intra-articular injections. The company was founded by Timothy J. Patrick and Peter J. Pizzo, III in 2005 and is headquartered in Alpharetta, GA.

Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA.

The Society of Kauffman Fellows is a venture capital fellowship program that aims to foster innovative leaders. The non-profit company is based in Palo Alto, CA. The program lasts for two years and includes industry events, summits, and a venture capital fund. The CEOs of the company are Jeff Harbach, Costello Trish.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Moximed, Inc. develops minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Its Osteoarthritis treatment can minimize joint pain, restore normal activity levels, and slow down disease progression. The company was founded by Anton G. Clifford in 2006 and is headquartered in Hayward, CA.

Cartiva, Inc. develops and manufactures medical devices. It provides devices for patients with osteoarthritis, cartilage damage and other musculoskeletal conditions. The company was founded in 2011 and is headquartered in Alpharetta, GA.

The Bill & Melinda Gates Foundation Trust (Foundation Trust), formerly known as William H. Gates Foundation, is a private foundation headquartered in Seattle, Washington. It was founded by Bill and Melinda Gates in 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation (established in 1994), which focused on improving global health. The Foundation Trust manages the endowment assets. They participate in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries.

Affinivax, Inc. operates as a biotechnology company which develops novel conjugation technology. The company is headquartered in North Cambridge, MA.

eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA.

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.

Variant Bio, Inc. is a biotechnology company, which engages in the development of new generation of therapeutics. It focuses on traits of medical relevance and using genomics. The company was founded by Akhila Kosaraju, Kaja Wasik, and Stephane Castel in 2018 and is headquartered in New York, NY.

Proxima Therapeutics, Inc. develops radiation delivery systems for the treatment of solid cancerous tumors. The CEO of the American company is Timothy J. Patrick.

Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation.

Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum.